DRUG
A Phase 2 Trial Testing ZP1848 in Patients With SBS
Status
Completed
Phase
Phase 2
Enrollment
18
Locations
1
Results
Not posted
Publications
3
Study summary
What the protocol is testing.
A proof-of-concept, dose finding, controlled, single-center, randomized, double-blind, fixed dose phase 2 trial with ZP1848 in patients with Short Bowel Syndrome.
Interventions
Treatment arms and agents.
Timeline
From registration to results.
First posted
Feb 24, 2016
Study start
Feb 2016
Primary completion
May 2017
Study completion
May 2017
Results posted
Not reported
Registry updated
Jun 21, 2017
Outcomes
What the study measures.
Primary outcomes
The Primary endpoint is the absolute change from baseline to the end of three week treatment periods of wet weight of ostomy output or diarrhea measured separately over each of the two treatment periods.
Time frame · 3 weeks
Secondary outcomes
Relative change from baseline to the end of treatment of wet weight of ostomy output or diarrhea measured separately over each of the two treatment periods
Time frame · 3 weeks
Absolute change from baseline to the end of treatment of urine weight measured separately over each of the two treatment periods
Time frame · 3 weeks
Relative change from baseline to the end of treatment of urine weight measured separately over each of the two treatment periods
Time frame · 3 weeks
Absolute change from baseline to the end of treatment of wet weight absorption measured separately over each of the two treatment periods
Time frame · 3 weeks
Relative change from baseline to the end of treatment of wet weight absorption measured separately over each of the two treatment periods
Time frame · 3 weeks
Absolute change from baseline to the end of treatment of the intestinal absorption of electrolytes measured separately over each of the two treatment periods
Time frame · 3 weeks
Relative change from baseline to the end of treatment of the intestinal absorption of electrolytes measured separately over each of the two treatment periods
Time frame · 3 weeks
Absolute change from baseline to the end of treatment of the intestinal absorption of macronutrients measured separately over each of the two treatment periods
Time frame · 3 weeks
Relative change from baseline to the end of treatment of the intestinal absorption of macronutrients measured separately over each of the two treatment periods
Time frame · 3 weeks
Change in SF-36 score
Time frame · 3 weeks
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 90 Years
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Following receipt of verbal and written information about the trial, the patient must provide signed informed consent before any trial related activity is carried out. * Age ≥ 18 years and ≤ 90 years * Stable SBS patients with intestinal insufficiency or failure, where the last surgical resection of gut tissue was performed at least 1 year ago * A stable PS volume ( \< 25% change in volume or energy content) for four weeks prior to randomization for patients requiring PS * Wet weight of fecal excretion ≥ 1500 g/day demonstrated during a hospital stay prior to screening or during at least one day of the first baseline balance study. * Stable body weight (\<5% weight deviance in the three months prior to screening) Exclusion Criteria: * Patients with known or suspected intestinal strictures of clinical relevance as judged by the Investigator * Active inflammatory bowel disease (IBD) or fistula during the screening period as judged by conventional means of the Investigator. * Crohn's disease patients not being in clinical remission for the last 12 weeks prior to randomization * Cardiac disease defined as: Decompensated heart failure (NYHA class III-IV) and/or diagnosis of unstable angina pectoris and/or myocardial infarction within the last 6 months prior to screening * History of cancer (except resected cutaneous basal or squamous cell carcinoma and except in situ cervical cancer) unless it can be documented that the patient has been in a disease-free state for at least 5 years (except colon cancer: patients with a history of colon cancer generally have to be excluded) * eGFR (by the MDRD formula) \<30 mL/min/1.73 m2 * Clinically meaningful renal disease as judged by the Investigator
Study locations
1 registered sites.
Denmark. Showing up to 24 locations stored in the fast local snapshot.
Rigshospitalet
Copenhagen, Denmark
Publications
Results and literature.
PMID 34287979 ↗Hvistendahl MK, Naimi RM, Hansen SH, Rehfeld JF, Kissow H, Pedersen J, Dragsted LO, Sonne DP, Knop FK, Jeppesen PB. Bile acid-farnesoid X receptor-fibroblast growth factor 19 axis in patients with short bowel syndrome: The randomized, glepaglutide phase 2 trial. JPEN J Parenter Enteral Nutr. 2022 May;46(4):923-935. doi: 10.1002/jpen.2224. Epub 2021 Sep 1.PMID 31326433 ↗Naimi RM, Hvistendahl M, Nerup N, Ambrus R, Achiam MP, Svendsen LB, Gronbaek H, Moller HJ, Vilstrup H, Steensberg A, Jeppesen PB. Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome: findings from a randomised phase 2 trial. EBioMedicine. 2019 Aug;46:444-451. doi: 10.1016/j.ebiom.2019.07.016. Epub 2019 Jul 17.PMID 30880176 ↗Naimi RM, Hvistendahl M, Enevoldsen LH, Madsen JL, Fuglsang S, Poulsen SS, Kissow H, Pedersen J, Nerup N, Ambrus R, Achiam MP, Svendsen LB, Holst JJ, Hartmann B, Hansen SH, Dragsted LO, Steensberg A, Mouritzen U, Hansen MB, Jeppesen PB. Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial. Lancet Gastroenterol Hepatol. 2019 May;4(5):354-363. doi: 10.1016/S2468-1253(19)30077-9. Epub 2019 Mar 15.
Related trials
More studies on Glepaglutide.
NCT IDStudyPhase / statusEnrollmentUpdated
Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome
Zealand Pharma · Short Bowel Syndrome (SBS)
Phase 3
Active, not recruiting
28
2026-07
Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
Zealand Pharma · Short Bowel Syndrome
Phase 3
Recruiting
90
2026-04
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial
Zealand Pharma · Short Bowel Syndrome
Phase 3
Active, not recruiting
129
2026-02
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
Zealand Pharma · Short Bowel Syndrome
Phase 3
Active, not recruiting
145
2026-01
Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)
Zealand Pharma · Short Bowel Syndrome
Phase 3
Completed
106
2025-07
The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome
Zealand Pharma · Short Bowel Syndrome
Phase 3
Completed
12
2024-11
A Bridging Trial to Compare the PK Profile When Glepaglutide is Administered Via Vial/Syringe Versus Autoinjector.
Zealand Pharma · Healthy
Phase 1
Completed
85
2021-07
Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal Function
Zealand Pharma · Renal Impairment
Phase 1
Completed
16
2020-11
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.